hympavzi
(marstacimab-hncq)Pfizer Laboratories Div Pfizer Inc
Usage: HYMPAVZI is indicated for routine prophylaxis to prevent or reduce bleeding episodes in patients aged 12 and older with hemophilia A (factor VIII deficiency) or hemophilia B (factor IX deficiency), both without inhibitors.